Cancer Cachexia Market Positioned for Accelerated Development Through 2034, DelveInsight Finds

DelveInsight's "Cancer Cachexia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Cancer Cachexia, historical and forecasted epidemiology as well as the Cancer Cachexia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Cancer Cachexia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cancer Cachexia Market Forecast
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Cancer Cachexia Market Report:
• In 2025, the Cancer Cachexia market size across the seven major markets (7MM) was valued at USD 483 million and is expected to grow at a CAGR of 8.9%, reaching approximately USD 1,038 million by 2034.
• DelveInsight estimates that there were roughly 1.4 million diagnosed prevalent cases of cancer cachexia across the 7MM in 2024, with the numbers projected to grow by 2034.
• The United States accounted for about 44% of these cases, totaling nearly 610,000 in 2024, and this figure is expected to rise throughout the 2025-2034 forecast period.
• Within the EU4 and the UK, Germany had the highest diagnosed prevalence at around 145,000 cases, while Spain reported the lowest at approximately 80,000.
• In Japan, there were about 215,000 diagnosed cases in 2024, a number also anticipated to increase by 2034.
• DelveInsight's analysis indicates a clear male predominance in cancer cachexia, with 60% of diagnosed cases in the US in 2024 occurring in men and 40% in women.
• Among the EU4 and the UK, colorectal cancer contributed the largest share of cancer cachexia cases at about 22%, whereas melanoma of the skin accounted for the smallest portion at roughly 2%.
• In 2024, Japan recorded around 323 cancer cachexia cases in people under 20, about 9,000 cases among those aged 20-44, roughly 65,000 cases in the 45-64 age group, and nearly 140,000 cases in individuals aged 65 and above. These figures are projected to rise by 2034.
• Key Cancer Cachexia Companies: Helsinn Healthcare, Ono Pharmaceutical, Endevica Bio, Pfizer, Actimed Therapeutics, Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics, Acacia Pharma, Helsinn Therapeutics, Novartis, Vicus Therapeutics, Celgene, CSL Behring, Helsinn Therapeutics, and others
• Key Cancer Cachexia Therapies: ADLUMIZ (anamorelin hydrochloride), Ponsegromab (PF-06946860), TCMCB07, ACM-001, PF 06946860, AV-380, EXT418, GTx-024, MT-102, Infliximab; Gemcitabine, Macimorelin, RC-1291, APD209, RC-1291, BYM338, VT-122, Lenalidomide, ALD518, Anamorelin HCl, and others
• The Cancer Cachexia epidemiology based on gender analyzed that through various secondary studies it can be concluded that cancer cachexia affects both males and females equally
• The Cancer Cachexia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cancer Cachexia pipeline products will significantly revolutionize the Cancer Cachexia market dynamics.

Cancer Cachexia Overview
A wasting illness known as cancer cachexia is typified by anemia, asthenia, anorexia (lack of appetite), and weight loss. This syndrome's multifaceted pathogenicity results from the intricate interplay between host and tumor components. Patients with advanced cancer, chronic heart failure, rheumatoid arthritis, chronic infection, including AIDS and tuberculosis, and chronic obstructive pulmonary disease are among those who experience it.

Get a Free sample for the Cancer Cachexia Market Report
https://www.delveinsight.com/report-store/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Cachexia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Cancer Cachexia Epidemiology Segmentation:
The Cancer Cachexia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Diagnosed Prevalent Cases of Cancer Cachexia
• Gender-specific Cases of Cancer Cachexia
• Tumor type-specific Cases of Cancer Cachexia
• Age-specific Cases of Cancer Cachexia

Download the report to understand which factors are driving Cancer Cachexia epidemiology trends @ Cancer Cachexia Epidemiology Forecast
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Cachexia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cancer Cachexia market or expected to get launched during the study period. The analysis covers Cancer Cachexia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Cancer Cachexia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Cancer Cachexia Therapies and Key Companies
• ADLUMIZ (anamorelin hydrochloride): Helsinn Healthcare/Ono Pharmaceutical
• Ponsegromab (PF-06946860): Pfizer
• TCMCB07: Endevica Bio
• ACM-001: Actimed Therapeutics
• PF 06946860: Pfizer
• AV-380: Aveo Oncology
• EXT418: Extend Biosciences
• GTx-024: GTx
• MT-102: Akamis Bio
• Infliximab; Gemcitabine: Centocor, Inc.
• Macimorelin: AEterna Zentaris
• RC-1291: Helsinn Therapeutics
• APD209: Acacia Pharma
• RC-1291: Helsinn Therapeutics
• BYM338: Novartis
• VT-122: Vicus Therapeutics
• Lenalidomide: Celgene
• ALD518: CSL Behring
• Anamorelin HCl: Helsinn Therapeutics

Discover more about therapies set to grab major Cancer Cachexia market share @ Cancer Cachexia Treatment Market
https://www.delveinsight.com/sample-request/cancer-cachexia-cc-market-insights?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Cancer Cachexia Market Drivers
• Increasing Global Cancer Burden: Rising incidence of advanced-stage cancers such as lung, pancreatic, gastric, and colorectal cancer is expanding the patient pool for cachexia treatment.
• Growing Awareness of Cachexia as a Distinct Clinical Condition: Shift from viewing cachexia as a secondary symptom to a treatable metabolic disorder is driving targeted therapeutic development.
• R&D Focus on Multifactorial and Combination Therapies: Surge in clinical trials exploring appetite stimulants, anti-inflammatory agents, anabolic therapies, and metabolic modulators.
• Advancements in Biomarker Research and Precision Medicine: Improved understanding of metabolic pathways, cytokines, and muscle degradation mechanisms supports personalized treatment strategies.
• Supportive Regulatory Initiatives & Orphan Drug Designations: Fast-track and orphan designations are accelerating development of novel drugs for cancer-associated cachexia.

Cancer Cachexia Market Barriers
• Lack of Approved and Effective Standard Therapies: Only a few symptomatic treatments exist, with limited efficacy and high unmet clinical need.
• Complex and Multifactorial Disease Mechanism: Involves inflammation, metabolic imbalance, and muscle wasting, making drug development challenging.
• High Failure Rate in Clinical Trials: Many investigational therapies fail due to difficulty defining endpoints, heterogeneous patient population, and late-stage diagnosis.
• Limited Awareness and Underdiagnosis in Early Stages: Cachexia is often recognized only in severe stages, reducing treatment window and clinical benefit.
• Cost and Reimbursement Challenges: Novel multimodal therapies may be expensive, and reimbursement uncertainty affects patient accessibility, especially in developing regions.

Scope of the Cancer Cachexia Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Cancer Cachexia Companies: Helsinn Healthcare, Ono Pharmaceutical, Endevica Bio, Pfizer, Actimed Therapeutics, Pfizer, Aveo Oncology, Extend Biosciences, GTx, Akamis Bio, Centocor, Inc., AEterna Zentaris, Helsinn Therapeutics, Acacia Pharma, Helsinn Therapeutics, Novartis, Vicus Therapeutics, Celgene, CSL Behring, Helsinn Therapeutics, and others
• Key Cancer Cachexia Therapies: ADLUMIZ (anamorelin hydrochloride), Ponsegromab (PF-06946860), TCMCB07, ACM-001, PF 06946860, AV-380, EXT418, GTx-024, MT-102, Infliximab; Gemcitabine, Macimorelin, RC-1291, APD209, RC-1291, BYM338, VT-122, Lenalidomide, ALD518, Anamorelin HCl, and others
• Cancer Cachexia Therapeutic Assessment: Cancer Cachexia current marketed and Cancer Cachexia emerging therapies
• Cancer Cachexia Market Dynamics: Cancer Cachexia market drivers and Cancer Cachexia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Cancer Cachexia Unmet Needs, KOL's views, Analyst's views, Cancer Cachexia Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.